


PHARMACEUTICAL 2022



BIODELIVERY SCIENCES INTERNATIONAL INC Rank 15 of 475







PHARMACEUTICAL 2022



BIODELIVERY SCIENCES INTERNATIONAL INC Rank 15 of 475



The relative strengths and weaknesses of BIODELIVERY SCIENCES INTERNATIONAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIODELIVERY SCIENCES INTERNATIONAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 401% points. The greatest weakness of BIODELIVERY SCIENCES INTERNATIONAL INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 515% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	202,065
Cost of Goods Sold	23,373
Intangible Assets	2,715
Liabilities, Current	82,378
Liabilities, Non-Current	219
Other Assets	119,816
Other Compr. Net Income	0
Other Expenses	-55,238
Other Liabilities	54,177
Other Net Income	-7,502
Property and Equipment	0
Research and Development	0
Revenues	166,703
Selling, General and Administrative Expense	106,206

Output Variable	Value in 1000 USD
Assets	324,596
Liabilities	136,774
Expenses	74,341
Stockholders Equity	187,822
Net Income	84,860
Comprehensive Net Income	84,860
Economic Capital Ratio	239%